Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

New Research Links Daytime Sleepiness, Alzheimer’s Disease

By Kenny Walter | September 7, 2018

Frequent midday naps may be refreshing, but the urge to take them could be a symptom of something more serious.

Researchers from Johns Hopkins University have found that adults who report daytime sleepiness were almost three times more likely to develop deposits of beta amyloid proteins in the brain, which has long been associated with Alzheimer’s disease, than those who do not.

 “Factors like diet, exercise and cognitive activity have been widely recognized as important potential targets for Alzheimer’s disease prevention, but sleep hasn’t quite risen to that status—although that may well be changing,” Adam Spira, PhD, an associate professor in the Department of Mental Health at the Johns Hopkins Bloomberg School of Public Health, said in a statement.

“If disturbed sleep contributes to Alzheimer’s disease, we may be able to treat patients with sleep issues to avoid these negative outcomes,” he added.

The researchers examined data from the Baltimore Longitudinal Study of Aging (BLSA), a long-term study that began in 1958, following the health of volunteers as they age. Between 1991 and 2000, the volunteers filled out questionnaires about their sleeping habits.

A subgroup of the study volunteers also received neuroimaging assessments, beginning in 1994. Also, in 2005, another subgroup of participants received a positron emission tomography (PET) scan using Pittsburgh compound B (PiB)—a radioactive compound that helps to identify amyloid plaques in neuronal tissue.

The team found 123 participants who both answered the questionnaire in the 90s and had a PET scan with PiB an average of almost 16 years later. The researchers then analyzed the data to try to find a correlation between participants who reported daytime sleepiness or took daytime naps and whether they scored positive for beta-amyloid deposition in their brains.

Before adjusting for demographic factors like age, sex, education and body-mass index, the researchers found that those who reported daytime sleepiness were about three times more likely to have beta-amyloid depositions than those who did not.

After adjusting for the demographic factors, the team found a risk that was still 2.75 times higher for those who reported daytime sleepiness.

According to Spira, it is not yet fully understood why daytime sleepiness was correlated with the deposition of beta-amyloid protein. He said one theory is that daytime sleepiness could cause the proteins to form.

However, previous research suggests that disturbed sleep due to factors like sleep apnea causes beta-amyloid plaques to form through an unknown mechanism.

Animal studies in Alzheimer’s disease models have shown that restricting nighttime sleep can lead to more beta-amyloid protein in the brain and spinal fluid and various human studies have linked poor sleep with greater measures of beta-amyloid in neuronal tissue.

“There is no cure yet for Alzheimer’s disease, so we have to do our best to prevent it,” Spira said. “Even if a cure is developed, prevention strategies should be emphasized. Prioritizing sleep may be one way to help prevent or perhaps slow this condition.”


Filed Under: Neurological Disease

 

Related Articles Read More >

An 8-year-old patient with gangliosidosis demonstrates improved mobility, walking unassisted on a soccer field after treatment with N-acetyl-L-leucine. (Still from video footage; parental consent obtained for use).
Modified amino acid approved for Niemann–Pick shows promise in early Parkinson’s research
AI-guided hunt points to PHGDH as an upstream drug target in Alzheimer’s disease
Why smaller, simpler molecular glues are gaining attention in drug discovery
Randy Bateman, MD, talks with research technician Olatayo Ajenifuja about Alzheimer’s Disease research in his lab on January 4, 2024, in the Neuroscience Research Building. MATT MILLER/WASHINGTON UNIVERSITY SCHOOL OF MEDICINE
Discontinued Alzheimer’s drug shows surprising long-term promise in genetic form of the disease
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE